Latest news with #KIT
Time of India
12 hours ago
- Business
- Time of India
Ukraine war sparks shift as young Germans warm to careers in defence industry
Representative Image In a notable shift for a country long defined by post-war pacifism, a growing number of young Germans are rethinking careers in the defence sector, driven by the ongoing war in Ukraine and broader global instability. German arms manufacturers, traditionally absent from public recruitment events, participated for the first time in a job fair at Karlsruhe Institute of Technology (KIT), a sign of changing tides. Students like 25-year-old Mika Scheid, an engineering student at KIT, are leading the shift. The Russian invasion of Ukraine was a 'personal turning point,' said Scheid, who joined the armed forces as a reservist and now hopes to work in military equipment manufacturing. 'People are beginning to understand that the Bundeswehr (the German armed forces) is now clearly focused on defending the country and Nato,' he said. Despite student protests prompting Rheinmetall to pull out of the fair, interest in the arms industry appears to be growing. Uncertainty about US security guarantees in Europe and economic stagnation are also pushing young professionals to consider the defence sector, once viewed with suspicion. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo 'The political discourse we have had since 2022 has led Germans to change their way of seeing things,' said Eva Brueckner of Heinrich and Coll, a headhunting firm that recruits for the defence industry. Since Russia's full-scale invasion of Ukraine over three years ago, ethical hesitations about the field have declined, she said. Companies are offering perks to lure fresh talent from relocation aid to gym memberships. Diehl, a major arms producer, is even offering scholarships to students, hoping to recruit them long-term. Nico Haenelt, a 19-year-old mechatronics student, attended the fair looking for an internship with Thyssenkrupp's submarine division. While his parents held pacifist views, he admitted, 'If the world were more peaceful, I would probably also look in other areas.' The European defence industry employs around 600,000 people and is projected to expand, especially under Chancellor Friedrich Merz, who has pledged to increase military spending. In the wake of job losses in other sectors, companies like Rheinmetall which recently absorbed workers from struggling auto supplier Continental and are becoming stabilisers for the broader economy. Still, attracting talent isn't easy. 'The sector is very conservative, and people who don't come from this background may have difficulty integrating,' said Brueckner. For some students, the stigma remains. Niklas, a computer science student, said he was looking for a job with 'meaning,' ideally in health or sustainability. The arms industry? 'Never,' he said.
Yahoo
14-05-2025
- Business
- Yahoo
Jasper Therapeutics to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences: RBC Capital Markets 2025 Global Healthcare Conference Conference Dates: May 20-21, 2025Presentation Date/Time: Wednesday, May 21, 2025; 11:00 a.m. EDTPresentation Format: Fireside Chat Jefferies 2025 Global Healthcare ConferenceConference Dates: June 3-5, 2025Presentation Date/Time: Thursday, June 5, 2025; 11:40 a.m. EDTPresentation Format: Presentation Live webcasts of the presentations will be available on the News & Events – Events page of Jasper's Investor Relations website. An archived replay of each presentation will be available on Jasper's website for 30 days following the applicable live broadcast. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; and Jasper's participation in the RBC Capital Markets 2025 Global Healthcare Conference and the Jefferies 2025 Global Healthcare Conference. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@ Joyce Allaire (investors)LifeSci Advisors617-435-6602jallaire@ Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@
Yahoo
03-05-2025
- Business
- Yahoo
Here's Why Third Harmonic Bio (THRD) Fell in Q1
1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to (4.3)% and (9.5)% for the S&P 500 (SPX) and Russell 2000 (RTY). Since its inception in February 2018, the fund has returned annualized net returns of 19.5%, compared to 11.9% and 4.8% for the indexes. In addition, you can check the fund's top 5 holdings to find out its best picks for 2025. In its first-quarter 2025 investor letter, 1 Main Capital highlighted stocks such as Third Harmonic Bio, Inc. (NASDAQ:THRD). Third Harmonic Bio, Inc. (NASDAQ:THRD) is a biopharmaceutical company. The one-month return of Third Harmonic Bio, Inc. (NASDAQ:THRD) was 48.28%, and its shares lost 55.90% of their value over the last 52 weeks. On May 1, 2025, Third Harmonic Bio, Inc. (NASDAQ:THRD) stock closed at $5.16 per share with a market capitalization of $232.76 million. 1 Main Capital stated the following regarding Third Harmonic Bio, Inc. (NASDAQ:THRD) in its Q1 2025 investor letter: "Third Harmonic Bio, Inc. (NASDAQ:THRD) came public in 2022, and its shares quickly came under pressure after the company reported that THB001, its primary drug, caused liver toxicity issues in trials. In February 2025, phase 1 data for another pipeline asset, THB335 ('335'), also disappointed investors. A close-up of a microscope, revealing the details of a small-molecule KIT inhibitor. Third Harmonic Bio, Inc. (NASDAQ:THRD) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held Third Harmonic Bio, Inc. (NASDAQ:THRD) at the end of the fourth quarter, compared to 16 in the third quarter. While we acknowledge the potential of Third Harmonic Bio, Inc. (NASDAQ:THRD) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Times
25-04-2025
- Business
- Business Times
DBS downgrades Keppel Infrastructure Trust to ‘hold', keeps Mapletree Logistics Trust at ‘buy'
[SINGAPORE] Analysts from DBS Group Research are mixed on some real estate investment trusts (Reits) this earnings season: They have kept their 'buy' rating on logistics-focused Mapletree Logistics Trust (MLT), but have downgraded Keppel Infrastructure Trust (KIT) to 'hold'. This is amid widespread economic uncertainty – mainly from the recent US-China trade war – which risks ripple effects on their portfolios. The target prices have been lowered to S$1.55 from S$1.75 for MLT, and to S$0.45 from S$0.57 for KIT. While MLT's Q4 distribution per unit (DPU) fell by 11.6 per cent to S$0.01955, DBS' Dale Lai and Derek Tan said that it was 'well-anticipated by the market'. The analysts said in their Thursday (Apr 24) report that stripping out the Reit's divestment gains of S$27 million, compared with S$41.5 million from the year before, its core FY2025 DPU would have come in at S$0.07519, down 7.9 per cent year on year instead. 'The drop was due to lower contribution from China, divested properties and general currency weakness against the Singapore dollar, mitigated by stronger performance from the Reit's Singapore, Australia and Hong Kong properties, coupled with acquisitions,' they wrote. A NEWSLETTER FOR YOU Tuesday, 12 pm Property Insights Get an exclusive analysis of real estate and property news in Singapore and beyond. Sign Up Sign Up Additionally, the manager of the Reit also decided to hold back from distributing its past undistributed divestment gains, in light of the market uncertainty brought about by the US-China trade war. Its leverage remained stable, but was at the higher end of the historical range at 40.7 per cent. This amounted to around S$19 million, which the analysts deemed a prudent move. They noted that the trust's leverage ratio was affected by a year-end devaluation exercise, coupled with the manager taking on more debt for acquisitions. Still, the trade war raises business uncertainties and could affect prospects in the medium term, wrote the analysts. However, MLT's exposure being substantially insulated – with 85 per cent of its portfolio revenue from domestic demand – suggests minimal impact from the tariffs, they said. At its current price, the Reit trades at a price-to-book ratio of 0.9 times and offers a yield of over 6 per cent, which is attractive, the analysts noted. 'If interest rates ease, we expect stronger allocations into S-Reits (Singapore-listed Reits), especially those with defensive sector exposure,' they added. Meanwhile, analyst Suvro Sarkar has a more 'cautious' stance on KIT, citing the concerns over the stability of distribution income. 'For a business trust like KIT, cash flows are expected to be predictable, and for a long time, they were – even during the Covid-19 period,' he wrote in an Apr 23 note. However, since 2023, cash flow has been harder to predict and its timing has been less consistent, with one-offs and adjustments. This does not make for a great reading, he warned. 'Distribution income in both 2023 and 2024 came in lower than 2022 levels, and distributions in 2023 were shored up by proceeds from 'capital optimisation' (or debt refinancing) – a trend that is concerning,' he wrote. In the company's Q1 business update released on Tuesday, a loss of S$678,000 was noted for the distribution income under the Philippine Coastal segment due to higher debt repayment of S$5.2 million. The trustee-manager noted that Q1 distributable income will fall by 31.9 per cent on the year to S$45.5 million after adjusting for one-offs as well. Looking ahead, higher-than-expected capital expenditure (capex) – of both maintenance and growth types – could again lead to volatility in distribution income. He also noticed that while the trust's balance sheet presents no immediate concerns, it is 'more stretched than before', with its gearing metrics above 40 per cent before the Philippine Coastal disposal, and are above the Monetary Authority of Singapore's guidelines for S-Reits. 'We see limited further debt headroom for growth, and KIT may need to tap the equity market for any future transactions,' he said. 'The question is – at current yields of around 10 per cent, can public equity markets be the reliable funding source KIT is looking for? And how will that affect the trust's ability to grow?' he asks. To Sarkar, though the trust is trading at a healthy yield, the weak share price performance in the year to date implies that KIT 'needs to inspire more confidence' in its ability to generate stable cash flows. As at 1.10 pm on Friday, units of KIT were trading 1.2 per cent or S$0.005 down at S$0.40. Units of MLT were trading 4.1 per cent or S$0.05 lower at S$1.16.
Business Times
25-04-2025
- Business
- Business Times
Keppel Infrastructure Trust downgraded to ‘hold'; Mapletree Logistics Trust ‘buy' call maintained: DBS
[SINGAPORE] Analysts from DBS Group Research are mixed on some real estate investment trusts (Reits) this earnings season – where they have kept their 'buy' rating on logistics-focused Mapletree Logistics Trust (MLT), but downgraded Keppel Infrastructure Trust (KIT) to hold. This is amid widespread economic uncertainty – mainly from the recent US-China trade war – which risks ripple effects on their portfolios. The target prices for both trusts have been lowered to S$1.55 from S$1.75 for MLT, and S$0.45 from S$0.57 for KIT. While MLT's Q4 distribution per unit (DPU) fell by 11.6 per cent to S$0.01955, DBS' Dale Lai and Derek Tan said that it was 'well-anticipated by the market'. The analysts explained in their Thursday (Apr 24) report that stripping out the Reit's divestment gains of S$27 million, compared with S$41.5 million from a year earlier, its core FY2025 DPU would have come in at S$0.07519, down 7.9 per cent year on year instead. 'The drop was due to lower contribution from China, divested properties and general currency weakness against the Singapore dollar, mitigated by stronger performance from the Reit's Singapore, Australia and Hong Kong properties, coupled with acquisitions,' they wrote. A NEWSLETTER FOR YOU Tuesday, 12 pm Property Insights Get an exclusive analysis of real estate and property news in Singapore and beyond. Sign Up Sign Up Additionally, the manager of the Reit also decided to hold back from distributing its past undistributed divestment gains, in the light of market uncertainty brought about by the US-China trade war. Its leverage remained stable, but was at the higher end of the historical range at 40.7 per cent. This amounted to around S$19 million, which the analysts deemed a prudent move. They noted that the trust's leverage ratio was affected by a year-end devaluation exercise, coupled with the manager taking on more debt for acquisitions. Still, the trade war still raises business uncertainties and could affect prospects in the medium term, wrote the analysts. However, as MLT's exposure is substantially insulated with 85 per cent of portfolio revenue from domestic demand, it suggests minimal impact from the tariffs, they explained. At its current price, the Reit trades at a price-to-book ratio of 0.9 times and offers a yield of over 6 per cent, which is attractive, the analysts noted. 'If interest rates ease, we expect stronger allocations into S-Reits (Singapore-listed Reits), especially those with defensive sector exposure,' they added. Meanwhile, analyst Suvro Sarkar has a more 'cautious' stance on KIT, citing how there may be concerns over the stability of distribution income. 'For a business trust like KIT, cash flows are expected to be predictable, and for a long time, they were – even during the Covid-19 period,' he explained in an Apr 23 note. However, since 2023, cash flow has been harder to predict and its timing has been less consistent, with one-offs and adjustments. This does not make for a great reading, warned the analyst. 'Distribution income in both 2023 and 2024 came in lower than 2022 levels, and distributions in 2023 were shored up by proceeds from 'capital optimisation' (or debt refinancing) – a trend that is concerning,' he wrote. Looking ahead, higher-than-expected capital expenditure (capex) – of both maintenance and growth types – could again lead to volatility in distribution income. He also noticed that while the trust's balance sheet presents no immediate concerns, it is 'more stretched than before', with its gearing metrics above 40 per cent before the Philippine Coastal disposal, and are above the Monetary Authority of Singapore's guidelines for S-Reits. 'We see limited further debt headroom for growth, and KIT may need to tap the equity market for any future transactions,' he said. 'The question is – at current yields of around 10 per cent, can public equity markets be the reliable funding source KIT is looking for? And how will that affect the trust's ability to grow?' he asks. To Sarkar, though the trust is trading at a healthy yield, the weak share price performance year to date highlights that KIT 'needs to inspire more confidence' in its ability to generate stable cash flows. As at 1.10 pm on Friday, units of KIT were trading 1.2 per cent or S$0.005 down at S$0.40. Units of MLT were trading 4.1 per cent or S$0.05 lower at S$1.16.
